Treatment of chronic viral hepatitis C in children and adolescents: UK experience

Archives of Disease in Childhood

Volumn 99, Issue 6, 2014, Pages 505-510

  Abdel Hady, M ^a   Bansal, S ^b   Davison, S M ^c   Brown, M ^a   Tizzard, S A ^b   Mulla, S ^c   Barnes, E ^d   Davies, P ^a   Mieli Vergani, G ^b   Kelly, D A ^a  

^a BIRMINGHAM CHILDREN S HOSPITAL   (United Kingdom)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

^c LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN; THYROID ANTIBODY; VIRUS RNA; INTERLEUKIN 28B; PEGINTERFERON ALPHA;

ADOLESCENT; ADOLESCENT DISEASE; ANEMIA; ARTICLE; BODY HEIGHT; BODY WEIGHT; CHILD; CHILDHOOD DISEASE; DEMOGRAPHY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; FEVER; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GENOTYPE; HEALTH CENTER; HEPATITIS C; HUMAN; INFLUENZA; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; MOOD CHANGE; NEUTROPENIA; PRIORITY JOURNAL; QUALITY OF LIFE; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT OUTCOME; UNITED KINGDOM; VIRUS LOAD; HEPATITIS C VIRUS; PEDIATRIC HOSPITAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; TREATMENT RESPONSE;

HEPATOLOGY; INFECTIOUS DISEASES;

ADOLESCENT; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; GREAT BRITAIN; HEPATITIS C; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; POLYETHYLENE GLYCOLS; POLYMORPHISM, SINGLE NUCLEOTIDE; QUALITY OF LIFE; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME;

EID: 84901239667     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/archdischild-2013-304601     Document Type: Article

References (38)

1. Lavanchy D. The global burden of hepatitis C. Liver International 2009;29(s1):74-81.
2. Harris RJ, Ramsay M, Hope VD, et al. Hepatitis C prevalence in England remains low and varies by ethnicity: an updated evidence synthesis. Eur J Public Health 2012;22:187-92.
3. Rumbo C, Fawaz LR, Emre SH, et al. Hepatitis C in children: quaternary referral centre perspective. J Pediatr gastroenterol Nutr 2006;43:209-16. (Pubitemid 44180507)
4. Bortollotti F, Verucchi G, Camma C, et al. Long-Term course of Chronic Hepatitis C in Children: from viral clearance to End-Stage Liver Disease. Gastroenterology 2008;134:1900-7. (Pubitemid 351783258)
5. Guido M, Bortolotti F, Leandro G, et al. Fibrosis in chronic hepatitis C acquired in infancy: is it only a matter of time? Am J Gastroenterol 2003;98:660-3. (Pubitemid 36348541)
6. Jhaveri R, Grant W, Kuf TL, et al. The burden of hepatitis C virus infection in children: estimated direct medical costs over a 10-year period. J Pediatr 2006;148:353-8.
7. Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management and treatment of hepatitis C: an update. Hepatology 2009;49:1335-74.
8. Landgraf JL, Abetz L, Ware JE. Child Health Questionnaire (CHQ): A User's Manual. Boston, MA: Health Act, 1999.
9. Chief Medical Officer, Department of Health. PL CMO: Hepatitis C and blood transfusion look back. 1995.
10. Abdel-Hady M, Bunn S, Sira J, et al. Chronic hepatitis C in children-review of natural history at a national centre. J Viral Hepat 2011;18:e535-40.
11. Poynard P, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997;349:825-32. (Pubitemid 27129209)
12. Wirth S, Ribes-Koninckx C, Bortollotti F, et al. High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin. J Hepatol 2010;52:501-7.
13. Hadziyannis SJ, Sette H, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: consensus guidelines. Can J gastroenterol 2007;21(Suppl C):25C-34C.
14. Jara P, Hierro L, De la Vaga A, et al. Efficacy and safety of peginterferon-alpha2b and ribavirin combination therapy in children with chronic hepatitis C infection. Pediatr Infec Dis J 2008;27:142-8.
15. Baker RD, Dee D, Baker SS. Response to pegylated interferon alpha-2b and ribavirin in children with chronic hepatitis C. J Clin Gastroenterol 2007;41:111-14. (Pubitemid 46045679)
16. Sokal EM, Bourgois A, Stephenne X, et al. Peginterferon alpha-2a plus ribavirin for chronic Hepatitis C virus infection in children and adolescents. J Hepatolo 2010;52:827-31.
17. Schwarz KB, Gonzalez-Peralta RP, Murray KF, et al. The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C. Gastroenterology 2011;140:450-8.
18. Wirth S, Pieper-Boustani H, Lang T, et al. Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C. Hepatology 2005;41:1013-18. (Pubitemid 40593909)
19. Gonzalez-Peraltaa R, Kelly DA, Harper B, et al. Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children. Efficacy, safety, and pharmacokinetics. Hepatology. 2005;42:1010-18. (Pubitemid 43112667)
20. Wirth S, Lang T, Gehring S, et al. Recombinant alfa-interferon plus ribavirin therapy in children and adolescents with chronic hepatitis C. Hepatology 2002;36:1280-4. (Pubitemid 35253447)
21. Sulkowski M, Lawitz E, Shiffman ML, et al. Final results of the IDEAL (individualized dosing efficacy versus flat dosing to assess optimal pegylated interferon therapy) phase IIIb study. J Hepatol. 2008;48(Supp 2):S370-1.
22. Ming-Yung L, Chai-Yen D, Jee-Fu H, et al. Rapid Virological Response and Treatment Duration for Chronic Hepatitis C Genotype 1 Patients: A Randomized Trial. Hepatology 2008;47:1884-93.
23. Zeuzem S, Berg T, Moeller B, et al. Expert opinion on the treatment of patients with chronic hepatitis C. J Viral Hepat 2009;16:75-90.
24. Kamal SM, El Kamary SS, Shardell MD, et al. Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: the role of rapid and early virologic response. Hepatology 2007;46:1732-40.
25. Mangia A, Santoro R, Minerva N, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005;352:2609-17. (Pubitemid 41007847)
26. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399-401.
27. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-a and ribavirin therapy. Nat Genet 2009;41:1100-4.
28. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-[alpha] and ribavirin therapy for chronic hepatitis C. Nat Genet 2009;41:1105-9.
29. Rauch A, Kutalik Z, Descombes P, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010;138:1338e45.
30. Kurosaki M, Tanka Y, Nishida N, et al. Pre-treatment prediction of response to pegylated interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors. J Hepatol 2011;54:439-48.
31. Abdel-Aziz DH, Sabry NA, El-Sayed MH, et al. Efficacy and safety of pegylated interferon in children and adolescents infected with chronic hepatitis C: A preliminary study. J Pharm Prac 2011;24:203-10.
32. Al-Huthail YR. Neuropsychiatric side-effects of interferon alfa therapy for hepatitis C and their management: a review. Saudi J Gastroenterol 2006;12:59-67.
33. Wirth S, Kelly D, Sokal E, et al. Guidance for clinical trials for children and adolescents with chronic hepatitis C. J Pediatr Gastroenterol Nutr 2011;52:233-7.
34. Mack C, Gonzalez-Peralta RP, Gupta N, et al. NASPGHAN Practice Guidelines: Diagnosis and Management of Hepatitis C Infection in Infants, Children, and Adolescents. J pediatr gastroenterol Nutr 2012;54:838-55.
35. Kelly DA, Haber B, González-Peralta RP, et al. Durability of sustained response shown in paediatric patients with chronic hepatitis C who were treated with interferon alfa-2b plus ribavirin. J Viral Hepat 2012;19:263-70.
36. Bonkovsky HL, Woolley JM. Reduction of health related quality of life in chronic hepatitis C and improvement with interferon therapy: The Consensus Interferon Study Group. Hepatology 1999;29:264-70. (Pubitemid 29024012)
37. Forton DM, Thomas HC, Murphy CA, et al. Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology 2002;35:433-9. (Pubitemid 34106386)
38. Rodrigue JR, Balistreri W, Haber B, et al. Peginterferon with or without ribavirin has minimal effect on quality of life, behavioural/emotional, and cognitive outcomes in children. Hepatology 2011;53:1468-75.